Cryopreservation and Thaw Protocols — DMSO, Freezing Rates and Storage

Cryopreservation is the arrest of biological activity by cooling below the temperature at which the sample vitrifies, using a cryoprotectant to control what happens to water on the way down. Everything that matters in the practice follows from one problem: water forms ice, ice is destructive in two distinct and opposing ways, and the parameters of a protocol are the compromise between them.

The two-factor problem, which explains every parameter below

The framework below has been settled since Mazur’s two-factor work in the 1970s, and stating it first makes the rest of the page follow from one mechanism rather than read as a list of numbers to memorise.

Cooling a cell suspension freezes the extracellular water first. That concentrates the solutes in the remaining liquid, and water leaves the cell osmotically. What happens next depends on the rate.

Cooling regime	What happens	Injury mechanism
Too fast	The cell cannot lose water quickly enough to stay in osmotic equilibrium, so it remains supercooled and ice nucleates inside the cell	Intracellular ice formation — mechanically destructive to membranes and organelles
Too slow	The cell dehydrates thoroughly, but spends a long period exposed to a highly concentrated extracellular solution	Solution effects — prolonged exposure to high solute concentration, extreme volume reduction, membrane damage
Optimal	Enough dehydration to avoid intracellular ice, little enough time at high solute concentration to avoid solution effects	The compromise. It is a curve with a maximum, and the position of the maximum differs by cell type

This is why survival plotted against cooling rate is an inverted U rather than a monotonic curve, and why there is no universal best rate. The optimum depends on the cell’s water permeability and surface-to-volume ratio, which is why a protocol validated for one cell type is a starting point rather than a transfer.

It also explains why the widely used “1 °C per minute” habit is a habit rather than a law. It is a rate that sits near the optimum for many mammalian cell types of ordinary size, which is not the same as being correct for the one in your vial. Published optimisation of hiPSC-derived cardiomyocytes found a rapid cooling rate of 5 °C per minute and a low nucleation temperature of −8 °C to be optimal for that cell type — three to five times faster than the default, on cells that are larger than hiPSCs and have a large osmotically inactive volume.

DMSO: what it does and what it costs

Dimethyl sulfoxide is the standard permeating cryoprotectant. It enters the cell, lowers the freezing point, reduces the fraction of water that becomes ice at any given temperature, and moderates the rise in solute concentration during freezing. It is effective and it is cytotoxic at physiological temperature — which is the source of essentially every handling rule around it.

DMSO concentration (v/v)	Where it appears	Notes
10 percent	The long-standing default for most mammalian cell freezing media	Where the majority of commercial freezing media sit. Effective; the toxicity constraint is on exposure time and temperature, not on the concentration per se
5 percent	Used where DMSO load is a concern	Studied in the MSC microencapsulation work cited here as one of a series
2.5 percent and below	Reduced-DMSO strategies, generally with an enabling technology	In the cited MSC study, reducing DMSO to 2.5 percent with hydrogel microencapsulation reached the 70 percent viability threshold the authors set as the clinical minimum. Without the enabling technology, low DMSO is not simply a substitution
0 percent (DMSO-free)	An active research area, driven by clinical infusion concerns	The cited hiPSC-cardiomyocyte work reports best-performing DMSO-free formulations giving post-thaw recoveries over 90 percent against a DMSO control of 69.4 ± 6.4 percent, using a designed sugar/sugar-alcohol/amino-acid mixture. This is a specific formulation on a specific cell type, not a general result

The reason DMSO reduction is pursued at all is worth understanding, because it explains which buyers should care. For research use, DMSO in the vial is a nuisance you dilute away. For anything infused into a patient, the DMSO goes with the cells and carries documented infusion-related effects — which is why the DMSO-free literature is concentrated in cell therapy rather than in research supply. If you are buying research-grade material, a DMSO-free formulation is not automatically better for you and may be worse if it has been less extensively validated on your cell type.

The handling rules that follow from DMSO toxicity:

Keep the cell/DMSO suspension cold and brief before freezing. Add the freezing medium, get the vials into the freezing device, and do not leave the suspension sitting at room temperature.
On thaw, dilute or remove DMSO promptly, but dilute slowly. A cell full of DMSO dropped into plain medium takes on water osmotically and can lyse. Stepwise dilution over a minute or two, with gentle mixing, is the standard mitigation.
Whether to remove DMSO by centrifugation at all is a genuine trade-off: the wash removes the toxin and costs you a centrifugation, which itself kills fragile post-thaw cells. Some products are specified for direct dilution without a spin. Follow the product’s protocol rather than a general habit.

Controlled-rate versus passive freezing

Method	How it works	Rate control	Where it fits
Passive / isopropanol container	Vials in an insulated container in a −80 °C freezer; the container’s thermal mass sets the rate	Approximately 1 °C/min, uncontrolled and unrecorded, varying with freezer load and container condition	The overwhelming majority of research laboratory freezing. Cheap, adequate for robust cell types
Alcohol-free passive containers	Same principle, engineered insulation rather than isopropanol	Same nominal rate, no alcohol to replace on a schedule	A maintenance improvement rather than a performance one
Controlled-rate freezer (CRF)	Programmed liquid-nitrogen-injected cooling with a temperature probe and a recorded profile	Programmable rate, programmable hold, and — critically — controlled ice nucleation	Required where the profile must be reproducible and documented. Standard in GMP manufacture and in commercial cell banking

The parameter a controlled-rate freezer gives you that a passive container cannot is nucleation control. A supercooled sample releases latent heat when ice finally forms, and the resulting temperature spike is uncontrolled and varies vial to vial. The hiPSC-cardiomyocyte optimisation cited here treated nucleation temperature as a designed variable alongside cooling rate and identified −8 °C as optimal for that cell type — a parameter that is not accessible at all in a passive container.

That said, the evidence does not support treating controlled-rate freezing as universally superior. A retrospective comparison of 50 haematopoietic progenitor cell products found that mean total nucleated cell viability post-thaw was higher for controlled-rate freezing (74.2 ± 9.9 percent) than for passive freezing (68.4 ± 9.4 percent), but no significant difference in CD34+ cell viability (77.1 ± 11.3 percent versus 78.5 ± 8.0 percent) and no significant difference in days to neutrophil or platelet engraftment. The authors concluded that passive freezing is an acceptable alternative for that application.

The useful reading for a buyer is not “CRF is unnecessary” but rather: the aggregate viability figure and the functionally relevant figure can diverge, and the endpoint that matters is the one tied to function. This is the same lesson as in post-thaw viability, arriving from a different direction.

Storage: vapour phase versus liquid phase

Storage mode	Temperature	Advantages	Risks
Liquid-phase liquid nitrogen (immersed)	−196 °C, uniform	Coldest, most uniform, no vertical gradient	Liquid nitrogen enters imperfectly sealed vials, which can cause violent vial rupture on warming; and it is a transmission route for contamination between samples
Vapour-phase liquid nitrogen (above the liquid)	Typically −150 °C to −190 °C depending on height in the vessel	No free liquid to enter vials or carry contamination between them; the standard for cell banking	A vertical temperature gradient exists, so shelf position matters. Requires liquid level maintenance and monitoring
Mechanical −150 °C freezer	Around −150 °C	No cryogen logistics, no asphyxiation hazard, continuous monitoring	Depends on power and compressor reliability; a single point of failure without a backup plan
−80 °C mechanical freezer	−80 °C	Ubiquitous	Above the glass transition. Molecular mobility persists and viability degrades over months. Acceptable for short-term holding, not for archival storage

The contamination argument for vapour phase is not hypothetical. Experimental work on embryos stored in liquid nitrogen biobanks found that embryos stored in open devices in artificially contaminated liquid nitrogen became infected (12.5 percent), while none stored in closed devices were infected — and, in the other direction, storage of artificially infected embryos in open devices contaminated the biobank in every case tested. Earlier work on viral contamination in liquid nitrogen found that a substantial fraction of embryo batches exposed to bovine viral diarrhoea virus and bovine herpesvirus-1 in unsealed containers tested positive for viral association after storage.

Those are embryo studies in open vitrification devices, and the mechanism does not transfer directly to a sealed cryovial. But the finding that liquid nitrogen is a competent transfer medium between samples is the reason vapour-phase storage became standard practice for banks holding material from multiple sources, and it is why a supplier’s answer to “how is this stored” is a meaningful question rather than a formality.

The glass transition, around −130 °C, is the operational boundary. Below it, the sample is vitrified and molecular mobility is negligible. Above it, degradation resumes at a rate that rises steeply with temperature. This is why a dry-ice shipment that is delayed is a real failure rather than an inconvenience, and why a vial that has been sitting in the top of a poorly filled vapour vessel may not have been stored at the temperature the label implies.

Thaw: where more cells are lost than anywhere else

Thaw is fast, unforgiving, and the step where a buyer can destroy a good product without ever knowing it.

Warm rapidly. The reverse of the freezing problem applies: slow warming allows small ice crystals to recrystallise into large damaging ones. A 37 °C water bath or dry bead bath until a small ice crystal remains, typically in the region of a couple of minutes for a standard cryovial, is the near-universal instruction. Do not walk away, and do not let the vial sit warm.

Dilute slowly, in steps. Osmotic shock on rehydration is a real loss mechanism. Add warm medium dropwise over the first additions.

Do not vortex, do not pipette hard, and minimise centrifugation. Post-thaw cells are mechanically fragile in a way that pre-freeze cells are not.

Consider whether the product requires a ROCK inhibitor. Dissociated human pluripotent stem cells undergo dissociation-induced apoptosis, and the finding that a ROCK inhibitor permits survival of dissociated human embryonic stem cells is the basis of the near-universal inclusion of Y-27632 in pluripotent thaw and passage protocols. Whether your product needs it, at what concentration, and for how long, is a product-specific question — and if it does, the inhibitor is a variable in your experiment as well as a rescue.

Measure viability at a stated time, by a stated method. Delayed apoptosis means a count at 15 minutes and a count at four hours are different measurements of different things. See post-thaw viability.

Measure attachment, not just viability. Plating efficiency at a defined timepoint predicts your experiment; membrane integrity does not.

What to specify when buying, and what to ask

Item	Question	Why it matters to you
Freezing medium	What is the formulation, and is DMSO present at what concentration?	Determines your dilution and wash procedure, and whether DMSO carryover affects your assay
Serum content	Does the freezing medium contain serum, and is that acceptable in your system?	Serum-containing freeze media are common and can be a problem for defined or xeno-free workflows
Freezing method	Controlled-rate with a recorded profile, or passive?	Reproducibility between lots. A recorded profile is a real quality signal
Nucleation	Was nucleation controlled?	Only available with a CRF, and a designed variable for some cell types
Storage mode and temperature	Vapour phase, liquid phase, or mechanical? At what temperature, monitored how?	Determines both contamination risk and whether the vial has genuinely stayed below the glass transition
Shipping mode	Dry ice or dry shipper, and what temperature record accompanies it?	Dry ice is around −78 °C, above the glass transition. Acceptable for short transit; the record tells you whether transit was short
Cells per vial, at what point	Counted at freeze or post-thaw?	The two differ, and the difference is exactly the material you lose
Thaw protocol	The vendor’s exact procedure, including ROCK inhibitor use and whether to wash	Deviating from it invalidates any comparison to their data
Recommended time to first medium change	When, and with what	A common undocumented step that changes early survival

Boundary cases

Vitrification is not slow freezing. Vitrification uses very high cryoprotectant concentrations and extremely rapid cooling to solidify without ice formation at all. It is standard in reproductive biology and in some organoid and tissue applications, and it has different handling, different toxicity constraints and different warming requirements. Do not apply slow-freeze rules to a vitrified product.

Cryopreserving tissue is not cryopreserving cells. A three-dimensional construct has diffusion limits on cryoprotectant penetration and heat transfer that a cell suspension does not. Many engineered tissue products are not cryopreserved at all and ship fresh with a short shelf life, which is a logistics constraint rather than a technical oversight.

“Cryopreserved” does not mean “recoverable by you”. The supplier’s viability figure was obtained with the supplier’s thaw protocol, in the supplier’s hands, at their measurement timepoint. Your figure is a different measurement, and the gap between the two is where most first-vial disappointments live.

The one-line summary

Cryopreservation is a controlled compromise between intracellular ice and solution effects, with DMSO buying you room in the middle and every handling rule following from DMSO’s toxicity above freezing. Ask the supplier for the freezing medium, the freezing method, the storage mode and the exact thaw protocol — and treat any vial that has been above roughly −130 °C for an unrecorded period as an unknown rather than a product.

Cryopreservation and thaw: what the parameters mean and which ones matter